In the latest trading session,, 1.59 million X4 Pharmaceuticals Inc (NASDAQ:XFOR) shares changed hands as the company’s beta touched 0.67. With the company’s most recent per share price at $3.73 changed hands at -$0.41 or -9.90% at last look, the market valuation stands at $21.60M. XFOR’s current price is a discount, trading about -808.85% off its 52-week high of $33.90. The share price had its 52-week low at $2.67, which suggests the last value was 28.42% up since then. When we look at X4 Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.2 million shares, with the 3-month average coming to 130.48K.
Analysts gave the X4 Pharmaceuticals Inc (XFOR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended XFOR as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. X4 Pharmaceuticals Inc’s EPS for the current quarter is expected to be -4.29.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
Instantly XFOR was in red as seen in intraday trades today. With action -5.81%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -83.05%, with the 5-day performance at -5.81% in the red. However, in the 30-day time frame, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is 10.68% up. Looking at the short shares, we see there were 0.31 million shares sold at short interest cover period of 1.97 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need a downside of -24.33% from its recent market value. According to analyst projections, XFOR’s forecast low is 3 with 5 as the target high. To hit the forecast high, the stock’s price needs a -34.05% plunge from its current level, while the stock would need to tank 19.57% for it to hit the projected low.
X4 Pharmaceuticals Inc (XFOR) estimates and forecasts
Year-over-year growth is forecast to reach 1,294.52% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 1.9M. 6 analysts are of the opinion that X4 Pharmaceuticals Inc’s revenue for the current quarter will be 2.27M. The company’s revenue for the corresponding quarters a year ago was 563k and 560k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 237.48%. The estimates for the next quarter sales put growth at 305.71%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 47.41%. The 2025 estimates are for X4 Pharmaceuticals Inc earnings to decrease by -81.49%, but the outlook for the next 5-year period is at 50.77% per year.
XFOR Dividends
X4 Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Apr-30.
X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.44% of X4 Pharmaceuticals Inc shares while 57.02% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 58.44%. There are 57.02% institutions holding the X4 Pharmaceuticals Inc stock share, with BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC the top institutional holder. As of 2024-06-30, the company held 8.4393% of the shares, roughly 16.92 million XFOR shares worth $9.81 million.
NEA MANAGEMENT COMPANY, LLC holds the second largest percentage of outstanding shares, with 7.4769% or 14.99 million shares worth $8.69 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 159.1 shares estimated at $0.59 million under it, the former controlled 2.75% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.61% of the shares, roughly 150.9 shares worth around $0.56 million.
